Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating fatty liver, hepatitis and liver cirrhosis

A technology of fatty liver, medicine, applied in the field of medicine

Pending Publication Date: 2016-06-29
程潜
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The interferon that is often used now has a certain curative effect on chronic hepatitis B, hepatitis C, and hepatitis cirrhosis. For example, its stable response rate for the treatment of hepatitis C is only 15%-20% (the curative effect of interferon for the treatment of hepatitis C Research: Journal of Integrative Chinese and Western Hepatology: 2002-12, Issue 1, Page 56); however, the side effects are large, the recurrence rate is high, and the price is expensive, which is not suitable for the medical consumption level of our country

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating fatty liver, hepatitis and liver cirrhosis
  • Medicine for treating fatty liver, hepatitis and liver cirrhosis
  • Medicine for treating fatty liver, hepatitis and liver cirrhosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1 A kind of medicine for the treatment of fatty liver, hepatitis, liver cirrhosis

[0030] The drug is marine algae glycoprotein;

[0031] Said marine algae glycoprotein, in parts by weight, includes sugar 1%, protein 99%,

[0032] The molecular weight is 0.2kDa;

[0033] The marine algae are: cyanobacteria;

[0034] The sugar is a polysaccharide;

[0035] The polysaccharides include: xylose, fucose, arabinose, glucose, galactose, mannose, rhamnose;

[0036] The protein includes: asparagine, cysteine, lysine, arginine, serine, threonine, glutamic acid;

Embodiment 2

[0037] Embodiment 2 A kind of medicine for the treatment of fatty liver, hepatitis, liver cirrhosis

[0038] The drug is marine algae glycoprotein;

[0039] Said marine algae glycoprotein, in parts by weight, comprises sugar 12%, protein 85%,

[0040] The molecular weight is 28kDa;

[0041] The marine algae is: green algae;

[0042] The sugar is a polysaccharide;

[0043] The polysaccharides include: xylose, fucose, arabinose, glucose, galactose, mannose, rhamnose;

[0044] The protein includes: asparagine, cysteine, lysine, arginine, serine, threonine, glutamic acid.

Embodiment 3

[0045] Embodiment 3 A kind of medicine for the treatment of fatty liver, hepatitis, liver cirrhosis

[0046] The drug is marine algae glycoprotein;

[0047] Said marine algae glycoprotein, in parts by weight, comprises sugar 35%, protein 64%,

[0048] The molecular weight is 68kDa;

[0049] The marine algae are: red algae;

[0050] The sugar is a polysaccharide;

[0051] The polysaccharides include: xylose, fucose, arabinose, glucose, galactose, mannose, rhamnose;

[0052] The protein includes: asparagine, cysteine, lysine, arginine, serine, threonine, glutamic acid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides a medicine for treating fatty liver, hepatitis and liver cirrhosis. The medicine is a mixture of glycoprotein or polysaccharide and protein, or is polypeptide or protein. After the medicine is adopted for treatment for 3 months, the content of ALT is reduced to 41.5-45.9 IU / L, the content of TbiL is reduced to 37.3-42.6 mu mol / L, the content of Alb is reduced to 32.6-35.0 g / L, the content of HBV-DNA is reduced to 4.0-4.9 copies / mL, the sputum negative conversion rate of HbeAg is 75-82%, and the sputum negative conversion rate of HBV-DNA is 83-87%. The medicine is suitable for treating fatty liver, alcoholic liver, alcoholism, hepatic fibrosis, viral hepatitis, hepatalgia, abdominal distension, cancer and cirrhosis, has the characteristics of being safe and efficient, and being free of side effects, and has the functions of absorbing and metabolizing alcohol in the body, and eliminating alcoholism.

Description

technical field [0001] The invention relates to a medicine for treating fatty liver, hepatitis and liver cirrhosis, belonging to the technical field of medicine. Background technique [0002] The infection rate of hepatitis B virus in my country is about 60%-70%; the carrier rate of hepatitis B surface antigen accounts for about 7.18% of the total population. Based on this calculation, there are about 93 million people in the country who carry hepatitis B virus, of which about 30 million are hepatitis B patients. At present, there are many people suffering from jaundice A, hepatitis B disease, virus, and hepatitis B virus. Many reasons can cause or induce jaundice A, hepatitis B virus, and hepatitis B virus disease, such as excessive drinking, poor body resistance, poor immunity, Irregular diet, etc. For patients with liver disease, they are discriminated against to varying degrees in terms of family, marriage, school enrollment, employment, going abroad, and social interact...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61K31/715A61K31/7012A61P1/16A61P31/20A61P31/14A61K36/02
CPCA61K31/7012A61K31/715A61K36/02A61K36/195A61K36/315A61K36/704A61K36/752A61K36/88A61K38/16A61K2300/00A61P1/16A61K36/03A61K36/04A61K36/05A61K36/896A61K38/168A61K31/4025
Inventor 程潜徐宝贞程龙
Owner 程潜
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com